Sugi Predict

Sugi Predict / Compounds / SCHEMBL649491

SCHEMBL649491

SCHEMBL649491

O=Cc1ccc([N+](=O)[O-])c(OCc2ccccc2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ ALDH1A1 P00352 5/20 0.55
▸ HPGD P15428 3/20 0.55
▸ LMNA P02545 3/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.54
▸ HTT P42858 1/20 0.54
▸ MAOA P21397 1/20 0.51
▸ MAOB P27338 1/20 0.51
▸ BACE1 P56817 1/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ CYP2C19 P33261 1/20 0.47
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ CTSV O60911 1/20 0.46
▸ CTSL P07711 1/20 0.46
▸ CYP11B1 P15538 1/20 0.45
▸ CYP11B2 P19099 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4643645 0.89 CTSV (0.57) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL25244858 0.86 MAOA (0.52) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL30566112 0.86 MAOA (0.52) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL6929884 0.86 ALDH1A1 (0.57) MAPTALDH1A1HPGDLMNASMN1; SMN2
SCHEMBL5171423 0.84 BACE1 (0.47) MAPTALDH1A1LMNASMN1; SMN2BACE1
SCHEMBL4307546 0.84 RAB9A (0.48) MAPTALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL4307547 0.84 RAB9A (0.48) MAPTALDH1A1HPGDSMN1; SMN2HTT
SCHEMBL9380841 0.83 KDM4E (0.63) ALDH1A1HPGDLMNABACE1
SCHEMBL9380836 0.83 KDM4E (0.63) ALDH1A1HPGDLMNABACE1
SCHEMBL29014226 0.83 XDH (0.51) MAPTALDH1A1HPGDMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 — — EP disclosed
US-12583836-B2 Sulphonamide compounds Anaxis Pharma Pty Ltd (AU) 2026-03-24 — — US disclosed
EP-4168401-B1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-01-07 — — EP disclosed
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2025-03-06 — — US disclosed
EP-4452966-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2024-10-30 — — EP disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
US-20230227429-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-07-20 — — US disclosed
WO-2023115149-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-06-29 — — WO disclosed
EP-4168401-A1 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2023-04-26 — — EP disclosed
CN-115956070-A Sulfonamide compounds 阿纳克西斯制药股份有限公司 2023-04-11 — — CN disclosed
US-20040078904-A1 Novel compounds for hair coloring compositions WELLA OPERATIONS US, LLC 2004-04-29 — — US disclosed
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use COPPOLA GARY MARK 2004-02-05 — — US disclosed
WO-2003082841-A1 5-SUBSTITUTED 1,1-DIOXO-`1,2,5!THIAZOLIDINE-3-ONE DERIVATIVES AS PTPASE 1B INHIBITORS NOVARTIS AG (CH) 2003-10-09 — — WO disclosed
CN-1100759-C Xanthene and arcridine derivative and its use HOFFMANN LA ROCHE (CH) 2003-02-05 — — CN disclosed
US-20020065309-A1 Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists AFFYMAX, INC. 2002-05-30 — — US disclosed
WO-2002011732-A1 NOVEL BICYCLIC AND TRICYCLIC PYRROLIDINE DERIVATIVES AS GNRH ANTAGONISTS GLAXO GROUP LIMITED (GB) 2002-02-14 — — WO disclosed
CN-1178789-A Xanthene and arcridine derivative and its use HOFFMANN LA ROCHE (CH) 1998-04-15 — — CN disclosed
EP-0356234-B1 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1994-05-11 — — EP disclosed
US-5047411-A Antiulcer Agents, H2-Receptor Antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-09-10 — — US disclosed
EP-0356234-A2 New Benzazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250074891-A1 BIFUNCTIONAL SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP9 MAPT 187/4885ALDH1A1 4680/4885HPGD 1896/4885
US-12583836-B2 Sulphonamide compounds MLKL, RIPK3, CASP1 MAPT 1287/4885ALDH1A1 4265/4885HPGD 3144/4885
US-20230227429-A1 SULPHONAMIDE COMPOUNDS MLKL, RIPK3, CASP1 MAPT 165/4885ALDH1A1 4663/4885HPGD 1747/4885
US-20020065309-A1 Novel Bicyclic and tricyclic pyrrolidine derivatives as GnRH antagonists GNRHR, FSHR, LHCGR MAPT 4314/4885ALDH1A1 4778/4885HPGD 800/4885
US-20040078904-A1 Novel compounds for hair coloring compositions CYC1, HSD3B1, MT-CO1 MAPT 4469/4885ALDH1A1 9/4885HPGD 944/4885
US-20040023974-A1 Cyclic sulfamide derivatives and methods of use PTPRS, PTPA, PTPMT1 MAPT 4727/4885ALDH1A1 2575/4885HPGD 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.